Sale!

FISH-Monosomy 7 del7q31 for AML MDS Test Cost

Original price was: 1,500 د.إ.Current price is: 1,200 د.إ.

-20%

The “FISH-Monosomy 7 del7q31 for AML MDS Test” is a specialized diagnostic procedure aimed at detecting genetic abnormalities associated with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). This test specifically focuses on identifying the deletion of the q31 region on chromosome 7 (del7q31) or the complete loss of one copy of chromosome 7 (monosomy 7), both of which are significant genetic markers that can influence the prognosis and treatment strategies for patients with AML or MDS.

Fluorescence in situ hybridization (FISH) is the technology employed in this test, offering a highly sensitive and specific method for detecting genetic abnormalities at a chromosomal level. By using fluorescent probes that bind to specific DNA sequences on chromosome 7, this test can accurately identify the presence of monosomy 7 or deletion of the 7q31 region within the patient’s cells.

Conducted at DNA Labs UAE, a leading facility in genetic testing and analysis, the “FISH-Monosomy 7 del7q31 for AML MDS Test” is available for a cost of 1200 AED. The lab’s state-of-the-art technology and experienced professionals ensure precise and reliable test results, providing crucial information for the diagnosis, prognosis, and management of patients with AML and MDS.

Description

FISH-MONOSOMY 7 del7q31 FOR AML MDS Test

Test Name: FISH-MONOSOMY 7 del7q31 FOR AML MDS Test

Test Components: Monosomy 7/del7q31

Price: 1200.0 AED

Sample Condition: 5 mL (3 mL min.) whole blood OR 4 mL (2 mL min.) Bone Marrow from 2 Green Top (Sodium Heparin) tubes. Ship at 18-22°C. DO NOT FREEZE. Duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory.

Report Delivery: Sample Daily by 4 pm; Report 4 Working days

Method: FISH

Test Type: Cancer

Doctor: Oncologist, Hematologist

Test Department: CYTOGENETICS

Pre Test Information: Duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory.

Test Details:

Fish-Monosomy 7, also known as del7q31, is a genetic test used in the diagnosis and prognosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). This test utilizes fluorescence in situ hybridization (FISH) technique to detect the presence of a specific chromosomal abnormality, which is the loss of one copy of chromosome 7 (monosomy 7) or a deletion in the long arm of chromosome 7 (del7q31).

The loss or deletion of chromosome 7 is associated with a poor prognosis in AML and MDS, as it often leads to the development of more aggressive disease and resistance to treatment. Therefore, FISH-Monosomy 7/del7q31 test is crucial in determining the appropriate treatment approach and predicting the outcome for patients with AML or MDS.

Test Name	FISH-MONOSOMY 7 del7q31 FOR AML MDS Test
Components	*Monosomy 7/del7q31
Price	1200.0 AED
Sample Condition	5 mL (3 mL min.) whole blood OR 4 mL ( 2 mL min.) Bone Marrow from 2 Green Top (Sodium Heparin) tubes. Ship at 18-22?\u00f8C. DO NOT FREEZE. Duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory.
Report Delivery	Sample Daily by 4 pm; Report 4Working days
Method	FISH
Test type	Cancer
Doctor	Oncologist, Hematologist
Test Department:	CYTOGENETICS
Pre Test Information	Duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory.
Test Details	Fish-Monosomy 7, also known as del7q31, is a genetic test used in the diagnosis and prognosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). This test utilizes fluorescence in situ hybridization (FISH) technique to detect the presence of a specific chromosomal abnormality, which is the loss of one copy of chromosome 7 (monosomy 7) or a deletion in the long arm of chromosome 7 (del7q31). The loss or deletion of chromosome 7 is associated with a poor prognosis in AML and MDS, as it often leads to the development of more aggressive disease and resistance to treatment. Therefore, FISH-Monosomy 7/del7q31 test is crucial in determining the appropriate treatment approach and predicting the outcome for patients with AML or MDS.